Gennari et al.,[60] Rody et al.,[22] Zhang and Liu[61] showed independently that HER2 status is a marker of doxorubicin sensitivity in BC, with higher HER2 expression indicating higher sensitivity to the drug. This evidence concerns the gene ERBB2 and breast cancer.